双膦酸盐在多发性骨髓瘤中的应用：国际骨髓瘤工作组对梅奥诊所共识声明的回应。 - Suppr

Suppr

超能文献

Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement.

作者信息

Durie Brian G M

出版信息

Mayo Clin Proc. 2007 Apr;82(4):516-7; author reply 517-8. doi: 10.4065/82.4.516.

DOI:10.4065/82.4.516

PMID:17418085

Abstract

摘要

相似文献

Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement.

Mayo Clin Proc. 2007 Apr;82(4):516-7; author reply 517-8. doi: 10.4065/82.4.516.

Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration.

Cytokine. 2008 Aug;43(2):103-4. doi: 10.1016/j.cyto.2008.05.010. Epub 2008 Jun 27.

Osteonecrosis of the jaw and bisphosphonates.

N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102. doi: 10.1056/NEJM200507073530120.

The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.

Acta Pol Pharm. 2006 Sep-Oct;63(5):450-2.

[The complications during the therapy for multiple myeloma].

Vnitr Lek. 2006 Feb;52(2):115.

Multiple myeloma.

N Engl J Med. 2005 Feb 24;352(8):840-1; author reply 840-1. doi: 10.1056/NEJM200502243520823.

[Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].

Zhonghua Yi Xue Za Zhi. 2008 Nov 18;88(42):2986-7.

Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.

J Oral Maxillofac Surg. 2006 Jun;64(6):995-6. doi: 10.1016/j.joms.2006.03.002.

Survey of members of myeloma UK on biphosphonates-associated jaw osteonecrosis.

Br J Haematol. 2007 Nov;139(4):626-8. doi: 10.1111/j.1365-2141.2007.06730.x. Epub 2007 Oct 8.

[Avascular jaw osteonecrosis associated with bisphophonate therapy].

Recenti Prog Med. 2006 Mar;97(3):140-4.

引用本文的文献

Myeloma Bone Disease: A Comprehensive Review.

Int J Mol Sci. 2021 Jun 8;22(12):6208. doi: 10.3390/ijms22126208.

Multiple Myeloma Associated Bone Disease.

Cancers (Basel). 2020 Jul 30;12(8):2113. doi: 10.3390/cancers12082113.

Is De-escalated Bisphosphonates Therapy a Suitable Alternative to Standard Dosing in Malignant Tumor Patients With Bone Metastases: A Systematic Review and Meta-Analysis.

Front Oncol. 2019 Aug 14;9:774. doi: 10.3389/fonc.2019.00774. eCollection 2019.

Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction.

Crit Rev Oncol Hematol. 2019 May;137:18-26. doi: 10.1016/j.critrevonc.2019.02.011. Epub 2019 Feb 27.

Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures.

Dent J (Basel). 2016 Dec 1;4(4):45. doi: 10.3390/dj4040045.

Application of PET/CT in treatment response evaluation and recurrence prediction in patients with newly-diagnosed multiple myeloma.

Oncotarget. 2017 Apr 11;8(15):25637-25649. doi: 10.18632/oncotarget.11418.

Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?

Support Care Cancer. 2017 Feb;25(2):345-349. doi: 10.1007/s00520-016-3147-9. Epub 2016 Mar 9.

Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.

Bone Marrow Transplant. 2015 Oct;50(10):1306-11. doi: 10.1038/bmt.2015.125. Epub 2015 Jun 29.

Bone disease in multiple myeloma: pathophysiology and management.

Cancer Growth Metastasis. 2014 Aug 10;7:33-42. doi: 10.4137/CGM.S16817. eCollection 2014.

Bisphosphonate-related osteonecrosis of the jaw: historical, ethical, and legal issues associated with prescribing.

J Adv Pract Oncol. 2013 Jan;4(1):25-35.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验